![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 42, 38337-38340, October 19, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
/
Mouse Liver*
,
,
,
,
,
,
,
,
,
, and
From the
Department of Internal Medicine, Graduate
School of Medicine, University of Tokyo, Tokyo 113-8655, § Institute for Diabetes Care and Research, Asahi Life
Foundation, Tokyo, 100-0005, and ¶ Biomedical Research
Laboratories, Sankyo Corporation Ltd., Tokyo, 140-8710, Japan
Received for publication, April 3, 2001, and in revised form, August 14, 2001
| |
ABSTRACT |
|---|
|
|
|---|
Insulin receptor substrate
(IRS)-2 The pathogenesis of type 2 diabetes involves complex
interactions among multiple physiological defects. Transgenic and
knockout technology to create animal models of type 2 diabetes have had a major impact on assessment of the function of newly identified molecules implicated in the regulation of glucose homeostasis in
vivo (1). The insulin receptor substrate
(IRS)1 proteins play a key
role in signal transduction from the insulin receptor (reviewed in
Refs. 2-4). These molecules are major intracellular phosphorylation
targets of activated insulin receptor tyrosine kinase. The mammalian
IRS protein family contains at least four members, ubiquitous IRS-1 (5)
and IRS-2 (6), adipose tissue-predominant IRS-3 (7), and IRS-4, which
are expressed in thymus, brain, and kidney (8). The physiological roles
of each protein have been evaluated by gene targeting strategies.
IRS-1 Liver is a major target organ for insulin action,
contributing to energy storage in the fed state by regulating catabolic and anabolic pathways. Liver-specific insulin receptor knockout mice
exhibit dramatic insulin resistance (19). Insulin decreases gluconeogenic enzyme mRNAs (20) and increases lipogenic enzyme mRNAs. A transcription factor of sterol regulatory element-binding protein 1c (SREBP-1c) (21-23) or adipocyte differentiation and determination factor (24) plays a central role in insulin-mediated lipogenic enzyme induction. Although SREBP-1c expression is
up-regulated by insulin and glucose in vitro (22, 23, 25,
26), the in vivo significance of insulin or glucose in
SREBP-1c gene up-regulation is a matter of controversy. How SREBP-1c
expression is regulated in vitro and in vivo and
how SREBP-1c expression is involved in leptin action and insulin
resistance have been the focus of intensive research.
Because the organ responsible for insulin resistance in
IRS-2 Materials--
All chemicals used were from Sigma.
[ Animal Experiments--
IRS-1 Body Weight, Weight of Adipose Tissue, and Serum Leptin
Levels--
Body weight was assessed between 0900 and 1100 h. The
statistical significance of the differences in body mass between groups was determined by Student's t test (two-tailed). The weight
of the epididymal fat was measured as described previously (27). Leptin
was assayed with the enzyme-linked immunosorbent assay-based Quantikine
M mouse leptin immunoassay kit (R & D Systems, Minneapolis, MN)
according to the manufacturer's instructions.
Liver Triglyceride and Cholesterol Content--
The
triglyceride and cholesterol content of the liver was measured as
described previously (28).
Oligonucleotide Microarray Analysis--
Total liver RNA was
isolated from 16-week-old wild-type and IRS-2 Northern Blot Hybridization with cDNA Probes--
Northern
blot hybridization was carried out as described previously (26,
30-32). The cDNA probes for mouse SREBP-1, human SREBP-2, mouse
spot 14, mouse fatty acid synthase, rat ATP citrate-lyase, mouse malic
enzyme, and glucokinase were prepared by cloning reverse transcriptase-polymerase chain reaction products from mouse liver RNA
into TA cloning vectors (Invitrogen, Carlsbad, CA). The
corresponding bands were quantified by exposure of BAS 2000 to the
filters to with BAStation software (Fuji Photo Film Co., Ltd., Tokyo, Japan).
Leptin Administration--
Wild-type and IRS-2 Regulation of SREBP-1 Gene by Leptin--
Leptin (50 mg/kg/injection) or control saline was administered to 6-week-old
IRS-2 IRS-2 Expression of SREBP-1 and Downstream Target Genes Were Enhanced in
IRS-2 SREBP-1 Expression Was Increased in Euglycemic 6-Week-old
IRS-2 Leptin Lowered SREBP-1 Expression in IRS-2 We have demonstrated an induction of SREBP-1c gene expression in
the liver of diabetic insulin-resistant IRS-2 How does leptin resistance contribute to increased SREBP-1c gene
expression? As leptin reportedly increases glucose uptake and glucose
turnover in peripheral tissues, thus decreasing glucose influx into the
liver (37), leptin resistance may provoke an increased glucose influx
into liver. Because glucose influx into hepatocytes is one of the most
important up-regulators of SREBP-1 gene (25, 26), an enhanced liver
glucose uptake in leptin-resistant IRS-2 SREBP-1 gene up-regulation may possibly contribute to ameliorating
insulin resistance through bypassing the insulin requirement for energy
storage by inducing lipogenic and glucokinase genes (22, 23, 31).
Increased triglyceride content in the target tissue of insulin,
which is the result of SREBP-1 gene up-regulation, was reported to be
associated with insulin resistance. We speculate that SREBP-1 gene
up-regulation with fatty liver development may be a kind of adaptive
response in leptin-resistant over-nourished state, with liver taking up
excess energy from blood flow instead of peripheral tissues.
How does leptin resistance in IRS-2
/
mice develop diabetes because of insulin
resistance in the liver and failure to undergo
-cell hyperplasia.
Here we show by DNA chip microarray analysis that expression of the
sterol regulatory element-binding protein (SREBP)-1 gene, a downstream
target of insulin, was paradoxically increased in 16-week-old
IRS-2
/
mouse liver, where insulin-mediated
intracellular signaling events were substantially attenuated. The
expression of SREBP-1 downstream genes, such as the spot 14, ATP
citrate-lyase, and fatty acid synthase genes, was also increased.
Increased liver triglyceride content in IRS-2
/
mice
assures the physiological importance of SREBP-1 gene induction. IRS-2
/
mice showed leptin resistance; low dose leptin
administration, enough to reduce food intake and body weight in
wild-type mice, failed to do so in IRS-2
/
mice.
Interestingly, high dose leptin administration reduced SREBP-1
expression in IRS-2
/
mouse liver. Thus, IRS-2 gene
disruption results in leptin resistance, causing an SREBP-1 gene
induction, obesity, fatty liver, and diabetes.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mice are growth-retarded and insulin-resistant
(9, 10) but do not develop diabetes, because an alternate substrate
IRS-2 (10) or pp190 (11) compensates for the lack of IRS-1 in liver (11) and, at least in part, in skeletal muscle (12). In addition, hyperinsulinemia associated with
-cell hyperplasia effectively countervailed the insulin-resistant states (13). IRS-2
/
mice, however, developed diabetes because of inadequate
-cell proliferation combined with liver-insulin resistance (14-16). Mice lacking IRS-3 or IRS-4 had milder phenotypes (17, 18).
/
mice is the liver (16), we focused our research
on the liver and performed a global gene expression study by using
oligonucleotide microarrays. We discovered paradoxical SREBP-1c gene
induction in insulin-resistant IRS-2
/
mice liver, even
in the early euglycemic phase, indicating that neither insulin action
nor hyperglycemia was responsible for SREBP-1 gene induction. We
provided evidence to show that leptin resistance is causally related to
SREBP-1 gene induction. The molecular mechanism, as well as biological
relevance, of leptin resistance in the development of type 2 diabetes
is discussed.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]dCTP was obtained from PerkinElmer Life Sciences.
/
,
IRS-2
/
, and wild-type mice were prepared by
heterozygote intercrosses (9, 16). Mice were housed on a 12-h
light-dark cycle and were given ad libitum access to regular
chow MF consisting of 25% (w/w) protein, 53% carbohydrates,
6% fat, and 8% water (Oriental Yeast Co., Ltd., Osaka, Japan). All
experiments in this study were performed on male mice, except when
stated specifically that female mice were used.
/
mice
after 15 h of fasting by TRIZOL reagent (Life Technologies, Inc.).
RNA was analyzed as follows: cDNA and cRNA probe were
prepared as described previously (29). Hybridization, washing, and
staining of Affymetrix Genechip murine 11K probe arrays were
carried out in an Affymetrix hybridization oven and fluidics station
according to the Affymetrix technical manual. The arrays were scanned
with a Hewlett-Packard confocal laser scanner and visualized using Affymetrix Genechip 3.1 software. The -fold change in expression in
mutant mice versus wild-type mice was calculated using
Affymetrix Gene Chip 3.1 software.
/
mice were injected intraperitoneally once a day at 2100 h with
control saline or leptin (10 mg/kg/injection) (PeproTech EC Ltd.,
London, United Kingdom), and daily body mass and food intake were
monitored at 0900 and 2100 h (27). The statistical significance of
differences in body mass and food intake between groups was determined
using Student's t test (two-tailed).
/
mice at 0900, 1700, and 0100 h. Body weight
and food intake were monitored at 0900 and 2100 h. For the
experiments of regulation of SREBP-1 gene by leptin, leptin (50 mg/kg/injection) or control saline was administered to
IRS-2
/
mice at 0900 h, when fasting began, at
1700, and at 0100 h. Animals were sacrificed at 0900 h the
next day by cervical dislocation. The liver was excised, frozen on
liquid nitrogen, and maintained at
80 °C until it was
processed further.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
Mice Showed Increased Adiposity--
During
the course of experiment, we found that the amount of body fat per body
weight was increased in IRS-2
/
mice (Fig.
1A). The whole growth curve of
wild-type and IRS-2
/
mice from 6 to 16 weeks old
revealed that IRS-2
/
mice had gained more body weight
after 8 weeks of age before the development of diabetes (Fig.
1B). The proportion of the weight of epididymal fat to total
body weight was significantly increased in IRS-2
/
mice
at the age of 6 weeks before IRS-2
/
mice had more body
weight gain than wild-type mice (Fig. 1A). Moreover, the
serum leptin level was increased in IRS-2
/
mice (Fig.
1C), suggesting that these mice were leptin-resistant. By
contrast, epididymal fat weight as a proportion of body weight and the
serum leptin level of IRS-1
/
mice did not differ
significantly from the values in wild-type mice (Fig. 1, A
and C).

View larger version (26K):
[in a new window]
Fig. 1.
Increased adiposity in
IRS-2
/
mice. A, weight of epididymal
fat as a proportion of total body weight was measured in 6- and
16-week-old male wild-type (WT), IRS-1
/
, and
IRS-2
/
mice. B, left, growth
curve of wild-type and IRS-2
/
mice. Body weight
(0900-1100 h) of male wild-type and IRS-2
/
mice was
measured from 6- to 16-week-old. Right, body weight
(0900-1100 h) was measured in 16-week-old male wild-type,
IRS-1
/
, and IRS-2
/
mice. C,
serum leptin level was measured in 6-week-old male wild-type,
IRS-1
/
, and IRS-2
/
mice. Values are
expressed as the mean ± S.E. (n = 5~7), **,
p < 0.01 as compared with the wild-type.
N.S., difference not significant.
/
Mouse Liver According to the Results of DNA Chip
Analysis--
To understand the molecular mechanism of the development
of diabetes in IRS-2
/
mice, we performed an integrated
gene expression study using liver samples. Total RNA was isolated from
16-week-old wild-type, IRS-1
/
, and
IRS-2
/
mice and analyzed by murine 11K oligonucleotide
microarray (Affymetrix). Among the ~11K genes and expressed
sequence tags analyzed, there was detected an increased expression of
the two copies of the SREBP-1 gene in the liver from 16-week-old
IRS-2
/
mice in the fasted states (Fig.
2A). This result was
surprising, because insulin reportedly up-regulates SREBP-1 gene
expression whereas insulin-mediated intracellular signaling events,
including phosphatidylinositol 3-kinase activation, are decreased
substantially in IRS-2
/
mice (16), and because
euglycemic-hyperinsulinemic clamp study demonstrated insulin resistance
in the liver in IRS-2
/
mice (33). We also found
up-regulated expression of several SREBP-1c target genes, including the
spot 14, ATP citrate-lyase, fatty acid synthase, and malic enzyme, all
of which are involved in fatty acid synthesis (Fig. 2B). All
these findings were confirmed by Northern blot analysis. An enhanced
expression of SREBP-1 with an unaltered expression of SREBP-2 in the
fasted state (Fig. 2C), and the enhanced expression of its
target genes, including the spot 14, ATP citrate-lyase, fatty acid
synthase, and malic enzyme gene, in the fasted state was observed in
IRS-2
/
mice (Fig. 2D). In addition, RNase
protection assay revealed that SREBP-1c expression was up-regulated
specifically in IRS-2
/
mice (data not shown).
Consistent with these findings, the triglyceride content of
IRS-2
/
mouse liver was elevated significantly (Fig.
2E), confirming the physiological significance of an
enhanced SREBP-1c expression in IRS-2
/
mice. By
contrast, the cholesterol content of IRS-2
/
mouse liver
was slightly reduced, consistent with unaltered SREBP-1a and SREBP-2
expression (21).

View larger version (34K):
[in a new window]
Fig. 2.
Induction of SREBP-1 and its target genes
associated with an increased triglyceride content in
IRS-2
/
mice liver. A, total RNA
isolated from livers of 16-week-old wild-type, IRS-1
/
,
and IRS-2
/
mice was analyzed by murine Mu11K
oligonucleotide microarray (Affymetrix). The expression levels of
SREBP-1 in IRS-1
/
and IRS-2
/
mice were
compared with that in wild-type mice, and -fold change of expression in
mutant mice versus wild-type mice was calculated using
Affymetrix Genechip 3.1 software. B, expression of
SREBP-1c target genes in wild-type and IRS-2
/
mice was
analyzed, and -fold change of expression was as calculated as described
above. C, total RNA was extracted from liver of
fasted animals with each genotype at 16 weeks of age. The 20-µg
aliquots were subjected to Northern blot hybridization with the
indicated 32P-labeled cDNA probes. D,
Northern blot analysis for SREBP-1c target genes. FAS, fatty
acid synthase. E, livers from 6-week-old animals with each
genotype were subjected to triglyceride (TG) and cholesterol
(Chol.) content analysis as indicated. WT,
wild-type. Values are expressed as means ± S.E.
(n = 6). **, p < 0.01 compared with
the wild-type. N.S., difference not significant.
/
Mice--
Because SREBP-1 expression is reportedly induced
by glucose itself (25, 26), we assessed the involvement of
hyperglycemia in SREBP-1 gene induction in IRS-2
/
mice.
First, we examined the expression of SREBP-1 in the liver of 6-week-old
IRS-2
/
mice having normal glucose tolerance and found
an elevated expression of SREBP-1 gene (Fig.
3A). Moreover, a comparable
increment in SREBP-1 expression was detected in female
IRS-2
/
mice, which have better glucose tolerance than
male mice (Fig. 3B). Thus, hyperglycemia may not be the
cause of the SREBP-1 gene induction.

View larger version (38K):
[in a new window]
Fig. 3.
SREBP-1 gene induction under normal glucose
tolerance. A, total RNA was extracted from liver of
fasted wild-type and IRS-2
/
male (A) and
female (B) mice at 6 weeks of age, and 20-µg aliquots were
subjected to Northern blot hybridization with the
32P-labeled cDNA probes indicated.
/
Mouse
Liver--
Leptin resistance is known to be associated with
an increased SREBP-1 gene expression (34). To assess the leptin
action in IRS-2
/
mice, we administered the low dose
leptin to euglycemic 6-week-old IRS-2
/
mice with
increased adiposity and hyperleptinemia (see Fig. 1). The daily
intraperitoneal administration of leptin (10 mg/kg body weight per day)
was sufficient to reduce food intake and body weight in the wild-type
but failed to do so in IRS-2
/
mice (Fig.
4A). Thus,
IRS-2
/
mice were leptin-resistant even in the
euglycemic stage. Next we examined the effects of higher dose leptin
administration. We found that administration of a 50 mg/kg body weight
dose to 6-week-old IRS-2
/
mice three times a day
resulted in a significant decrease in food intake and body weight gain
(Fig. 4B). Moreover, administration of the same amount of
leptin into the fasted IRS-2
/
mice resulted in the
amelioration of SREBP-1 overexpression (Fig. 4C). Thus, a
high dose of leptin administration into leptin-resistant IRS-2
/
mice lowered the increased SREBP-1 expression in
the liver.

View larger version (36K):
[in a new window]
Fig. 4.
Leptin lowers SREBP-1 gene expression in
IRS-2
/
mice liver. A, leptin resistance
in IRS-2
/
mice. Wild-type (WT),
IRS-1
/
, and IRS-2
/
mice were injected
intraperitoneally with saline or leptin (10 mg/kg/injection) once a
day, at 2100 h, and body weight (BW) and food intake
were monitored daily at 0900 and 2100 h. Values are expressed as
means ± S.E. (n = 9). **, p < 0.01; ***, p < 0.001; N.S., difference not
significant. B and C, leptin (Lep) (50 mg/kg/injection) or control saline were administered to 6-week-old
IRS-2
/
mice three times a day. Food intake and body
weight were monitored (B). Total RNA was extracted from the
liver, and 20-µg aliquots were subjected to blot hybridization with
the indicated 32P-labeled cDNA probes (C).
NS, difference not significant.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mice.
This paradoxical finding prompted us to explore factors other than
insulin that induced SREBP-1 gene expression in IRS-2
/
mice. We showed that leptin resistance contributes, at least in part,
to the up-regulation of the SREBP-1 gene by demonstrating that high
dose leptin administration not only reduced food intake and body weight
but also ameliorated SREBP-1 overexpression in IRS-2
/
mice. Analogous situations were reported in ob/ob mice,
lipoatrophic mice (35, 36), and leptin-unresponsive obese Zucker
diabetic fatty fa/fa rats (34), suggesting that leptin resistance is linked causally to SREBP-1 gene induction in liver. We observed further
an up-regulated expression of SREBP-1 gene in goldthioglucose-treated leptin-resistant mice,2
indicating that leptin resistance in hypothalamus is involved directly
in SREBP-1 gene induction in liver.
/
mice causes
up-regulation of SREBP-1 gene expression, thus causing fatty liver. Our
hypothesis that leptin resistance is the cause of SREBP-1 gene
induction may explain why fatty liver is commonly observed among
insulin-resistant over-nourished obese type 2 diabetes patients with
relatively preserved insulin secretory function.
/
mice develop? Our
in vitro study showed that lack of IRS-2 had little effect
on insulin-stimulated glucose uptake in the isolated adipocytes of
IRS-2
/
mice.3
The almost normal insulin function in IRS-2
/
mice
adipocytes may cause an increased glucose and lipid uptake by these
cells in the presence of hyperinsulinemia, which was provoked by
liver-insulin resistance in IRS-2
/
mice, and thus
result in the enlargement of adipocytes. In accordance with the
observation that adipocyte hypertrophy is associated with leptin
resistance in the hypothalamus (38, 39), the obese 6-week-old
IRS-2
/
mice showed leptin resistance before developing
diabetes (see Fig. 1 and Fig. 4). Alternatively, lack of IRS-2 may
influence directly leptin signaling pathways in the hypothalamus,
because leptin-stimulated phosphorylation of signal transducers and
activators of transcription 3 in the hypothalamus is attenuated in
IRS-2
/
mice (40), and because neuron-specific insulin
receptor knockout mice showed leptin resistance (41).
| |
ACKNOWLEDGEMENTS |
|---|
We are grateful to Dr. Hitoshi Shimano for Northern blot probe of spot 14 and fatty acid synthase. We are grateful to Drs. Hidehiko Furukawa, Nobufusa Serizawa, and Norio Nakamura for supporting the experiments on DNA chips. We thank Dr. Kajuro Komeda, Dr. Mitsuhiko Noda, Dr. Kazuhiro Eto, Dr. Kazuo Hara, Dr. Katsuko Takasawa, Shoji Asai, Dr. Hitoshi Shimano, and Dr. Wataru Ogawa for helpful discussion. We thank G. Yu, A. Nagano, and H. Chiyonobu for excellent technical assistance and mouse husbandry.
| |
FOOTNOTES |
|---|
* This work was supported by Health Sciences research grants (for research on human genome and gene therapy) from the Ministry of Health and Welfare and Grant 1-2000-231 from the Juvenile Diabetes Foundation International (to T. K.), by a grant-in-aid for the development of innovative technology and a grant-in-aid for creative basic research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to T. K. and K. T.), and by a health sciences research grant from the Ministry of Health and Welfare (to R. N.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Internal
Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Tel.: 81-3-5800-8818; Fax:
81-3-5689-7209; E-mail: kadowaki-3im@h.u-tokyo.ac.jp.
Published, JBC Papers in Press, August 23, 2001, DOI 10.1074/jbc.C100160200
2 M. Aoyama, K. Tobe, R. Suzuki, and T. Kadowaki, unpublished observation.
3 S. Satoh, K. Tobe, R. Suzuki, and T. Kadowaki, unpublished observation.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: IRS, insulin receptor substrate; SREBP, sterol regulatory element-binding protein.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Kadowaki, T. (2000) J. Clin. Invest. 106, 459-465[Medline] [Order article via Infotrieve] |
| 2. | White, M. F. (1998) Mol. Cell. Biochem. 182, 3-11[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Virkamaki, A., Ueki, K., and Kahn, C. R. (1999) J. Clin. Invest. 103, 931-943[Medline] [Order article via Infotrieve] |
| 4. | Keller, S. R., and Lienhard, G. E. (1994) Trends Cell Biol. 4, 115-119[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | White, M. F., Maron, R., and Kahn, C. R. (1985) Nature 318, 183-186[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Sun, X. J., Wang, L. M., Zhang, Y., Yenush, L., Myers, M. G., Jr., Glasheen, E., Lane, W. S., Pierce, J. H., and White, M. F. (1995) Nature 377, 173-177[CrossRef][Medline] [Order article via Infotrieve] |
| 7. |
Lavan, B. E.,
Lane, W. S.,
and Lienhard, G. E.
(1997)
J. Biol. Chem.
272,
11439-11443 |
| 8. |
Lavan, B. E.,
Fantin, V. R.,
Chang, E. T.,
Lane, W. S.,
Keller, S. R.,
and Lienhard, G. E.
(1997)
J. Biol. Chem.
272,
21403-21407 |
| 9. | Tamemoto, H., Kadowaki, T., Tobe, K., Yagi, T., Sakura, H., Hayakawa, T., Terauchi, Y., Ueki, K., Kaburagi, Y., Satoh, S., Sekihara, H., Yoshioka, S., Horikoshi, H., Furuta, Y., Ikawa, Y., Kasuga, M., Yazaki, Y., and Aizawa, S. (1994) Nature 372, 182-186[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Araki, E., Lipes, M. A., Patti, M. E., Bruning, J. C., Haag, I. B., Johnson, R. S., and Kahn, C. R. (1994) Nature 372, 186-190[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Tobe, K.,
Tamemoto, H.,
Yamauchi, T.,
Aizawa, S.,
Yazaki, Y.,
and Kadowaki, T.
(1995)
J. Biol. Chem.
270,
5698-5701 |
| 12. | Yamauchi, T., Tobe, K., Tamemoto, H., Ueki, K., Kaburagi, Y., Yamamoto-Honda, R., Takahashi, Y., Yoshizawa, F., Aizawa, S., Akanuma, Y., Sonenberg, N., Yazaki, Y., and Kadowaki, T. (1996) Mol. Cell. Biol. 16, 3074-3084[Abstract] |
| 13. | Terauchi, Y., Iwamoto, K., Tamemoto, H., Komeda, K., Ishii, C., Kanazawa, Y., Asanuma, N., Aizawa, T., Akanuma, Y., Yasuda, K., Kodama, T., Tobe, K., Yazaki, Y., and Kadowaki, T. (1997) J. Clin. Invest. 99, 861-866[Medline] [Order article via Infotrieve] |
| 14. | Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J., Ren, J. M., Previs, S., Zhang, Y., Bernal, D., Pons, S., Shulman, G. I., Bonner-Weir, S., and White, M. F. (1998) Nature 391, 900-904[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Withers, D. J., Burks, D. J., Towery, H. H., Altamuro, S. L., Flint, C. L., and White, M. F. (1999) Nat. Genet. 23, 32-40[Medline] [Order article via Infotrieve] |
| 16. | Kubota, N., Tobe, K., Terauchi, Y., Eto, K., Yamauchim, T., Tsubamoto, Y., Komeda, K., Takazawa, K., Isogawa, A., Suzuki, R., Nakano, R., Waki, K., Hara, K., Aizawa, S., Noda, M., Akanuma, Y., Nagai, R., Accili, D., Kimura, S., Taylor, S., and Kadowaki, T. (2000) Diabetes 49, 1880-1889[Abstract] |
| 17. |
Liu, S. C.,
Wang, Q.,
Lienhard, G. E.,
and Keller, S. R.
(1999)
J. Biol. Chem.
274,
18093-18099 |
| 18. |
Fantin, V. R.,
Wang, Q.,
Lienhard, G. E.,
and Keller, S. R.
(2000)
Am. J. Physiol. Endocrinol. Metab.
278,
E127-E133 |
| 19. | Michael, M. D., Kulkarni, R. N., Postic, C., Previs, S. F., Shulman, G. I., Magnuson, M. A., and Kahn, C. R. (2000) Mol. Cell 6, 87-97[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
O'Brien, R. M.,
and Granner, D. K.
(1996)
Physiol. Rev.
76,
1109-1161 |
| 21. | Brown, M. S., and Goldstein, J. L. (1997) Cell 89, 331-340[CrossRef][Medline] [Order article via Infotrieve] |
| 22. |
Foretz, M.,
Guichard, C.,
Ferre, P.,
and Foufelle, F.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
12737-12742 |
| 23. |
Shimomura, I.,
Bashmakov, Y.,
Ikemoto, S.,
Horton, J. D.,
Brown, M. S.,
and Goldstein, J. L.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
13656-13661 |
| 24. |
Kim, J. B.,
and Spiegelman, B. M.
(1996)
Genes Dev.
10,
1096-1107 |
| 25. |
Foretz, M.,
Pacot, C.,
Dugail, I.,
Lemarchand, P.,
Guichard, C.,
LeLiepvre, X.,
Berthelier-Lubrano, C.,
Spiegelman, B.,
Kim, J.,
Ferre, P.,
and Foufelle, F.
(1999)
Mol. Cell. Biol.
19,
3760-3768 |
| 26. |
Shimano, H.,
Yahagi, N.,
Amemiya-Kudo, M.,
Hasty, A. H.,
Osuga, J.,
Tamura, Y.,
Shionoiri, F.,
Iizuka, Y.,
Ohashi, K.,
Harada, K.,
Gotoda, T.,
Ishibashi, S.,
and Yamada, N.
(1999)
J. Biol. Chem.
274,
35832-35839 |
| 27. | Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Nakano, R., Ishii, C., Sugiyama, T., Eto, K., Tsubamoto, Y., Okuno, A., Murakami, K., Sekihara, H., Hasegawa, G., Naito, M., Toyoshima, Y., Tanaka, S., Shiota, K., Kitamura, T., Fujita, T., Ezaki, O., Aizawa, S., Nagai, R., Tobe, K., Kimura, S., and Kadowaki, T. (1999) Mol. Cell 4, 597-609[CrossRef][Medline] [Order article via Infotrieve] |
| 28. |
Yokode, M.,
Hammer, R. E.,
Ishibashi, S.,
Brown, M. S.,
and Goldstein, J. L.
(1990)
Science
250,
1273-1275 |
| 29. | Lockhart, D. J., Dong, H., Byrne, M. C., Follettie, M. T., Gallo, M. V., Chee, M. S., Mittmann, M., Wang, C., Kobayashi, M., Horton, H., and Brown, E. L. (1996) Nat. Biotechnol. 14, 1675-1680[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Shimano, H., Horton, J. D., Hammer, R. E., Shimomura, I., Brown, M. S., and Goldstein, J. L. (1996) J. Clin. Invest. 98, 1575-1584[Medline] [Order article via Infotrieve] |
| 31. | Shimano, H., Horton, J. D., Shimomura, I., Hammer, R. E., Brown, M. S., and Goldstein, J. L. (1997) J. Clin. Invest. 99, 846-854[Medline] [Order article via Infotrieve] |
| 32. | Shimomura, I., Shimano, H., Horton, J. D., Goldstein, J. L., and Brown, M. S. (1997) J. Clin. Invest. 99, 838-845[Medline] [Order article via Infotrieve] |
| 33. |
Previs, S. F.,
Withers, D. J.,
Ren, J. M.,
White, M. F.,
and Shulman, G. I.
(2000)
J. Biol. Chem.
275,
38990-38994 |
| 34. |
Kakuma, T.,
Lee, Y.,
Higa, M.,
Wang, Z.,
Pan, W.,
Shimomura, I.,
and Unger, R. H.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
8536-8541 |
| 35. |
Shimomura, I.,
Bashmakov, Y.,
and Horton, J. D.
(1999)
J. Biol. Chem.
274,
30028-30032 |
| 36. | Shimomura, I., Matsuda, M., Hammer, R. E., Bashmakov, Y., Brown, M. S., and Goldstein, J. L. (2000) Mol. Cell 6, 77-86[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Kamohara, S., Burcelin, R., Halaas, J. L., Friedman, J. M., and Charron, M. J. (1997) Nature 389, 374-377[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Spiegelman, B. M., and Flier, J. S. (1996) Cell 87, 377-389[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Marsh, D. J., Hollopeter, G., Huszar, D., Laufer, R., Yagaloff, K. A., and Fish, S. I. (1999) Nat. Genet. 21, 119-122[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | Burks, D. J., Font de Mora, J., Schubert, M., Withers, D. J., Myers, M. G., Towery, H. H., Altamuro, S. L., Flint, C. L., and White, M. F. (2000) Nature 407, 377-382[CrossRef][Medline] [Order article via Infotrieve] |
| 41. |
Bruning, J. C.,
Gautam, D.,
Burks, D. J.,
Gillette, J.,
Schubert, M.,
Orban, P. C.,
Klein, R.,
Krone, W.,
Muller-Wieland, D.,
and Kahn, C. R.
(2000)
Science
289,
2122-2125 |
This article has been cited by other articles:
![]() |
A. Erhuma, A. M. Salter, D. V. Sculley, S. C. Langley-Evans, and A. J. Bennett Prenatal exposure to a low-protein diet programs disordered regulation of lipid metabolism in the aging rat Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1702 - E1714. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kamei, K. Tobe, R. Suzuki, M. Ohsugi, T. Watanabe, N. Kubota, N. Ohtsuka-Kowatari, K. Kumagai, K. Sakamoto, M. Kobayashi, et al. Overexpression of Monocyte Chemoattractant Protein-1 in Adipose Tissues Causes Macrophage Recruitment and Insulin Resistance J. Biol. Chem., September 8, 2006; 281(36): 26602 - 26614. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Biddinger, M. Miyazaki, J. Boucher, J. M. Ntambi, and C. R. Kahn Leptin Suppresses Stearoyl-CoA Desaturase 1 by Mechanisms Independent of Insulin and Sterol Regulatory Element-Binding Protein-1c. Diabetes, July 1, 2006; 55(7): 2032 - 2041. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang, G. Kouri, and C. B. Wollheim ER stress and SREBP-1 activation are implicated in {beta}-cell glucolipotoxicity J. Cell Sci., September 1, 2005; 118(17): 3905 - 3915. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Jiang, S. E. Liebman, M. S. Lucia, C. L. Phillips, and M. Levi Calorie Restriction Modulates Renal Expression of Sterol Regulatory Element Binding Proteins, Lipid Accumulation, and Age-Related Renal Disease J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2385 - 2394. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-S. Im, S.-Y. Kang, S.-Y. Kim, H.-i. Kim, J.-W. Kim, K.-S. Kim, and Y.-H. Ahn Glucose-Stimulated Upregulation of GLUT2 Gene Is Mediated by Sterol Response Element-Binding Protein-1c in the Hepatocytes Diabetes, June 1, 2005; 54(6): 1684 - 1691. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Suzuki, K. Tobe, M. Aoyama, K. Sakamoto, M. Ohsugi, N. Kamei, S. Nemoto, A. Inoue, Y. Ito, S. Uchida, et al. Expression of DGAT2 in White Adipose Tissue Is Regulated by Central Leptin Action J. Biol. Chem., February 4, 2005; 280(5): 3331 - 3337. [Abstract] [Full Text] [PDF] |
||||
![]() |
A M Diehl, Z P Li, H Z Lin, and S Q Yang Cytokines and the pathogenesis of non-alcoholic steatohepatitis Gut, February 1, 2005; 54(2): 303 - 306. [Full Text] [PDF] |
||||
![]() |
Y. Terauchi, J. Matsui, J. Kamon, T. Yamauchi, N. Kubota, K. Komeda, S. Aizawa, Y. Akanuma, M. Tomita, and T. Kadowaki Increased Serum Leptin Protects From Adiposity Despite the Increased Glucose Uptake in White Adipose Tissue in Mice Lacking p85{alpha} Phosphoinositide 3-Kinase Diabetes, September 1, 2004; 53(9): 2261 - 2270. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Suzuki, K. Tobe, M. Aoyama, A. Inoue, K. Sakamoto, T. Yamauchi, J. Kamon, N. Kubota, Y. Terauchi, H. Yoshimatsu, et al. Both Insulin Signaling Defects in the Liver and Obesity Contribute to Insulin Resistance and Cause Diabetes in Irs2-/- Mice J. Biol. Chem., June 11, 2004; 279(24): 25039 - 25049. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ahluwalia, K. H. Clodfelter, and D. J. Waxman Sexual Dimorphism of Rat Liver Gene Expression: Regulatory Role of Growth Hormone Revealed by Deoxyribonucleic Acid Microarray Analysis Mol. Endocrinol., March 1, 2004; 18(3): 747 - 760. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsuzaka, H. Shimano, N. Yahagi, M. Amemiya-Kudo, H. Okazaki, Y. Tamura, Y. Iizuka, K. Ohashi, S. Tomita, M. Sekiya, et al. Insulin-Independent Induction of Sterol Regulatory Element-Binding Protein-1c Expression in the Livers of Streptozotocin-Treated Mice Diabetes, March 1, 2004; 53(3): 560 - 569. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Shimizu, S. Ugi, H. Maegawa, K. Egawa, Y. Nishio, T. Yoshizaki, K. Shi, Y. Nagai, K. Morino, K.-i. Nemoto, et al. Protein-tyrosine Phosphatase 1B as New Activator for Hepatic Lipogenesis via Sterol Regulatory Element-binding Protein-1 Gene Expression J. Biol. Chem., October 31, 2003; 278(44): 43095 - 43101. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang, P. Maechler, P. A. Antinozzi, L. Herrero, K. A. Hagenfeldt-Johansson, A. Bjorklund, and C. B. Wollheim The Transcription Factor SREBP-1c Is Instrumental in the Development of beta -Cell Dysfunction J. Biol. Chem., May 2, 2003; 278(19): 16622 - 16629. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Akune, N. Ogata, K. Hoshi, N. Kubota, Y. Terauchi, K. Tobe, H. Takagi, Y. Azuma, T. Kadowaki, K. Nakamura, et al. Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts J. Cell Biol., October 14, 2002; 159(1): 147 - 156. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Rondinone, J. M. Trevillyan, J. Clampit, R. J. Gum, C. Berg, P. Kroeger, L. Frost, B. A. Zinker, R. Reilly, R. Ulrich, et al. Protein Tyrosine Phosphatase 1B Reduction Regulates Adiposity and Expression of Genes Involved in Lipogenesis Diabetes, August 1, 2002; 51(8): 2405 - 2411. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Scearce, J. E. Brestelli, S. K. McWeeney, C. S. Lee, J. Mazzarelli, D. F. Pinney, A. Pizarro, C. J. Stoeckert Jr., S. W. Clifton, M. A. Permutt, et al. Functional Genomics of the Endocrine Pancreas: The Pancreas Clone Set and PancChip, New Resources for Diabetes Research Diabetes, July 1, 2002; 51(7): 1997 - 2004. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sun, S. Liu, S. Ferguson, L. Wang, P. Klepcyk, J. S. Yun, and J. E. Friedman Phosphoenolpyruvate Carboxykinase Overexpression Selectively Attenuates Insulin Signaling and Hepatic Insulin Sensitivity in Transgenic Mice J. Biol. Chem., June 21, 2002; 277(26): 23301 - 23307. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Soulet and S. Rivest Perspective: How to Make Microarray, Serial Analysis of Gene Expression, and Proteomic Relevant to Day-to-Day Endocrine Problems and Physiological Systems Endocrinology, |